# A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma

> **NCT03331731** · PHASE2 · UNKNOWN · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 27 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT03331731
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-29
- **Primary completion:** 2023-02-16
- **Final completion:** 2024-07
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03331731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03331731, "A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT03331731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*